Terug
Dagbereik
€ 450,97
€ 463,78
52-Weeksbereik
€ 362,50
€ 513,98
Volume
1.152.006
50D / 200D Gem.
€ 469,18
/
€ 438,51
Vorige Slotkoers
€ 454,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 29,0 | 0,4 |
| P/B | 6,1 | 2,9 |
| ROE % | 22,5 | 3,7 |
| Net Margin % | 32,7 | 3,9 |
| Rev Growth 5Y % | 12,4 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Hold
€ 549,73
+21.8%
Low: € 441,00
High: € 607,00
Forward K/W
23,4
Forward WPA
€ 19,32
WPA Groei (sch.)
+0,0%
Omzet Sch.
13 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 33,61
€ 31,04 – € 37,27
|
20 B | 5 |
| FY2029 |
€ 29,57
€ 27,31 – € 32,79
|
18 B | 11 |
| FY2028 |
€ 25,20
€ 14,13 – € 35,75
|
16 B | 13 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2026 |
Bozic Carmen
EVP and CMO
|
sell | 2.329 | € 481,79 | € 1.122.089 |
| Mar 2, 2026 |
Liu Joy
EVP and Chief Legal Officer
|
sell | 892 | € 495,96 | € 442.396 |
| Feb 25, 2026 |
Biller Jonathan
EVP and Chief Legal Officer
|
sell | 945 | € 486,35 | € 459.601 |
| Feb 25, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
sell | 4.910 | € 486,35 | € 2.394.365 |
| Feb 24, 2026 |
Biller Jonathan
EVP and Chief Legal Officer
|
other | 1.144 | € 485,11 | € 554.966 |
| Feb 24, 2026 |
LEIDEN JEFFREY M
Executive Chairman
|
other | 3.547 | € 485,11 | € 1.720.685 |
| Feb 24, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
other | 873 | € 485,11 | € 423.501 |
| Feb 24, 2026 |
Kewalramani Reshma
CEO & President
|
other | 4.981 | € 485,11 | € 2.416.333 |
| Feb 24, 2026 |
Bozic Carmen
EVP and CMO
|
other | 1.453 | € 485,11 | € 704.865 |
| Feb 17, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
grant | 4.962 | — | — |
| Feb 17, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
other | 1.148 | € 483,75 | € 555.345 |
| Feb 13, 2026 |
Kewalramani Reshma
CEO & President
|
other | 13.041 | € 487,76 | € 6.360.878 |
| Feb 10, 2026 |
WAGNER CHARLES F JR
EVP, CO & FO
|
other | 3.045 | € 468,41 | € 1.426.308 |
| Feb 10, 2026 |
Sachdev Amit
EVP Chief Patient & Ext Af Off
|
other | 2.057 | € 468,41 | € 963.519 |
| Jan 22, 2026 |
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
|
grant | 11.749 | — | — |
| Jan 6, 2026 |
WAGNER CHARLES F JR
EVP, CO & FO
|
other | 19.064 | € 189,38 | — |
| Jan 6, 2026 |
WAGNER CHARLES F JR
EVP, CO & FO
|
sell | 9.532 | € 461,00 | € 4.394.252 |
| May 1, 2025 |
SACHS BRUCE I
Director
|
grant | 2.398 | — | — |
| May 1, 2025 |
CARNEY LLOYD
Director
|
grant | 796 | — | — |
| Apr 15, 2025 |
SACHS BRUCE I
Director
|
grant | 95 | € 497,51 | € 47.263 |
Belangrijkste Punten
Revenue grew 12,37% annually over 5 years — strong growth
ROE of 22,54% indicates high profitability
Net margin of 32,74% shows strong profitability
Debt/Equity of 0,21 — conservative balance sheet
Generating 3,19B in free cash flow
Cash machine — converts 80,79% of earnings into free cash flow
Groei
Revenue Growth (5Y)
12,37%
Revenue (1Y)9,57%
Earnings (1Y)N/A
FCF Growth (3Y)-1,31%
Kwaliteit
Return on Equity
22,54%
ROIC15,84%
Net Margin32,74%
Op. Margin39,43%
Veiligheid
Debt / Equity
0,21
Current Ratio2,90
Interest Coverage357,95
Waardering
P/E Ratio
28,99
P/B Ratio6,14
EV/EBITDA23,82
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9,57% | Revenue Growth (3Y) | 10,61% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | 4,51% |
| Revenue Growth (5Y) | 12,37% | Earnings Growth (5Y) | 13,98% |
| Profitability | |||
| Revenue (TTM) | 12,07B | Net Income (TTM) | 3,95B |
| ROE | 22,54% | ROA | 15,12% |
| Gross Margin | 85,03% | Operating Margin | 39,43% |
| Net Margin | 32,74% | Free Cash Flow (TTM) | 3,19B |
| ROIC | 15,84% | FCF Growth (3Y) | -1,31% |
| Safety | |||
| Debt / Equity | 0,21 | Current Ratio | 2,90 |
| Interest Coverage | 357,95 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 28,99 | P/B Ratio | 6,14 |
| P/S Ratio | 9,49 | PEG Ratio | -0,03 |
| EV/EBITDA | 23,82 | Dividend Yield | 0,00% |
| Market Cap | 114,61B | Enterprise Value | 113,41B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 12,07B | 11,02B | 9,87B | 8,93B | 7,57B |
| Net Income | 3,95B | -535,60M | 3,62B | 3,32B | 2,34B |
| EPS (Diluted) | 15,32 | -2,08 | 13,89 | 12,82 | 9,01 |
| Gross Profit | 10,27B | 9,49B | 8,61B | 7,85B | 6,67B |
| Operating Income | 4,76B | -232,90M | 3,83B | 4,31B | 2,78B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 26,14B | 22,53B | 22,73B | 18,15B | 13,43B |
| Total Liabilities | 7,48B | 6,12B | 5,15B | 4,24B | 3,33B |
| Shareholders' Equity | 18,67B | 16,41B | 17,58B | 13,91B | 10,10B |
| Total Debt | 3,88B | 1,75B | 808,40M | 899,70M | 967,40M |
| Cash & Equivalents | 5,09B | 4,57B | 10,37B | 10,50B | 6,80B |
| Current Assets | 11,20B | 9,60B | 14,14B | 13,23B | 9,56B |
| Current Liabilities | 3,86B | 3,56B | 3,55B | 2,74B | 2,14B |